Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

GAINL vs ABCL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

GAINL Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

GAINL Overall Winner 6-Pillar Tally: GAINL 3 – 3 ABCL Matrix Metrics: GAINL 6 – 4 ABCL

As of Nov 20, 2026, Gladstone Investment Corporation 8.00% Notes due 2028 (GAINL) is the stronger overall head-to-head candidate over AbCellera Biologics Inc. Common Shares (ABCL) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Options & Positioning, R&D & Supply-Chain Moat). GAINL carries a Unified Composite Score of 59.2/100 (HOLD) at $25.21 (N/M Forward P/E, 42.5% operating margin), whereas ABCL carries 57.1/100 (HOLD) at $9.69 (27.6x Forward P/E, -298.0% operating margin).

  • Technical & Structure Timing Caution: GAINL is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 44.0); meanwhile ABCL is in a Breakdown options structure phase (RSI 33.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GAINL vs ABCL
GAINL NASDAQ Head-to-Head Winner
Gladstone Investment Corporation 8.00% Notes due 2028
Institutional Equity
$25.21
+0.13% 1D
Market Cap $358.3M
TTM Revenue $64M
Forward P/E N/M
Beta / 30D Vol 0.02β · 2% Vol
Unified Composite Score
59.2 / 100 HOLD
Tech 60.0 Fund 52.0 Flow 50.0 Mom 48.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -0.7%) with fading momentum, RSI 44
RSI-14: 44.0 · SMA20: $25.19 · SMA50: $25.49
ABCL NASDAQ
AbCellera Biologics Inc. Common Shares
Pharmaceutical Preparations
$9.69
-7.45% 1D
Market Cap $3.4B
TTM Revenue $68M
Forward P/E 27.6x
Beta / 30D Vol 2.32β · 85% Vol
Unified Composite Score
57.1 / 100 HOLD
Tech 33.0 Fund 54.0 Flow 70.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 34
RSI-14: 33.8 · SMA20: $11.79 · SMA50: $12.30

6-Pillar Scorecard Institutional Category Breakdown (GAINL 3 – 3 ABCL)

Columns: Metric · GAINL · ABCL
1. Valuation Multiples ABCL
Forward P/E N/M 27.6x
Trailing P/E N/M 27.6x
PEG Ratio N/M N/M
EV / Revenue 5.6x 50.0x
2. Growth & Scale ABCL
Revenue Growth (YoY) +68.4% +18.8%
Earnings Growth (YoY) N/A +45.9%
TTM Revenue (USD) $64M $68M
Market Cap $358.3M $3.4B
3. Profitability & Quality GAINL
Gross Margin 88.6% N/A
Operating Margin 42.5% -298.0%
Net Profit Margin 140.1% -218.6%
Return on Equity (ROE) 22.9% -14.6%
4. Balance Sheet & Cash Flow ABCL
Cash Generation (TTM) N/A -$33M
Cash Flow Margin N/A -48.4%
Net Cash / Leverage $12.66 Book/Sh · 22.9% ROE $30M Net Cash
Dividend Yield 7.78% None (0.00%)
5. Options & Positioning GAINL
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 86.5% (32nd %ile)
Put/Call OI Skew N/A 0.35x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Distribution DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat GAINL
OpEx & R&D Intensity 46.1% of Rev ($29M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Specialty Finance Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GAINL (6) vs ABCL (4)
Institutional Metric GAINL ABCL Criterion Row Edge
Market Capitalization
Scale
$358.3M $3.4B Larger Scale ABCL
Trailing P/E Ratio
Valuation
N/M 27.6x Lower Multiple ABCL
Forward P/E Ratio
Valuation
N/M 27.6x Lower Multiple ABCL
Revenue Growth (YoY)
Growth
+68.4% +18.8% Higher Growth GAINL
Operating Margin (TTM)
Profitability
42.5% -298.0% Higher Margin GAINL
Net Profit Margin
Profitability
140.1% -218.6% Higher Margin GAINL
Return on Equity (ROE)
Capital Efficiency
22.9% -14.6% Higher ROE GAINL
52-Week Range Position
Momentum
9% ($25–$26) 57% ($3–$15) Stronger Trend ABCL
Beta / 30D Volatility
Risk Regime
0.02β · 2% Vol 2.32β · 85% Vol Lower Realized Risk GAINL
Unified Institutional Score
Composite Signal
59.2 / 100 (HOLD) 57.1 / 100 (HOLD) Higher Composite GAINL
Trailing 12M Revenue (USD)
Operating Scale
$64M $68M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
88.6% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 5.6x EV/Rev N/M PEG · 50.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($12.66 Book/Sh · 22.9% ROE) -$33M ($30M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GAINL +3.29 pp
GAINL: +0.24% · ABCL: -3.05%
3M Horizon GAINL +3.29 pp
GAINL: +0.24% · ABCL: -3.05%
6M Horizon GAINL +3.29 pp
GAINL: +0.24% · ABCL: -3.05%
1Y Horizon GAINL +3.29 pp
GAINL: +0.24% · ABCL: -3.05%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GAINL vs ABCL. Trailing 12-month operating profitability (GAINL 42.5% vs ABCL -298.0%) and valuation multiples (GAINL N/M vs ABCL 27.6x Forward P/E) are benchmarked directly in Pillar 4 below.

GAINL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$64M
Gross Margin88.6%
Op. Margin42.5%
ROE / Fwd P/E22.9% · N/M
ABCL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$68M
Gross MarginN/A
Op. Margin-298.0%
ROE / Fwd P/E-14.6% · 27.6x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GAINL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GAINL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABCL BREAKDOWN
38d in phase · OBV DISTRIBUTION
Current IV 86.5%
IV Percentile 32nd %ile
Put/Call OI Skew 0.35x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ABCL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $11.12 · IV 84.0%

ABCL Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($1,112)

Compare $1,112 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 84.0% ATM IV.

5-DAY BULLISH SWING Liq B

Dec 18 $12 / $13 Bull Call Spread

Buy 4x $12C · Sell 4x $13C · 32d

Net Entry $80 Debit
T+5d @ +5% Move +$25 (+31%)
Max Risk / Buffer $80 Capped
5d Edge & Liquidity 1.0x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Jan 15 '27 $10 / $9 Bull Put Spread

Sell 5x $10P · Buy 5x $9P · 60d

Net Entry $175 Credit
Max Credit / Yield +$175 (+53.8% RoM)
Max Risk / Buffer -13.2% Cushion ($325 Mgn)
5d Edge & Liquidity 70% PoP · Liq A
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq B

Dec 18 $12 / $10 Bear Put Spread

Buy 1x $12P · Sell 1x $10P · 32d

Net Entry $106 Debit
T+5d @ -5% Drop +$16 (+15%)
Max Risk / Buffer $106 Capped
5d Edge & Liquidity 0.7x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GAINL Moat Profile High-Margin Pricing Power Moat
Specialty Finance Operator
Competes within the Specialty Finance value chain with $358.3M market capitalization and 42.5% operating margin.
OpEx & R&D Reinvestment 46.1% of Rev ($29M)
90D Engineering Disclosures 0 Published
ABCL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.4B market capitalization and -298.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ GAINL vs ABCL Key Questions & Quantitative Answers

As of Nov 20, 2026, Gladstone Investment Corporation 8.00% Notes due 2028 (GAINL) is the stronger overall head-to-head candidate over AbCellera Biologics Inc. Common Shares (ABCL) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Options & Positioning, R&D & Supply-Chain Moat). GAINL carries a Unified Composite Score of 59.2/100 (HOLD) at $25.21 (N/M Forward P/E, 42.5% operating margin), whereas ABCL carries 57.1/100 (HOLD) at $9.69 (27.6x Forward P/E, -298.0% operating margin). Technical & Structure Timing Caution: GAINL is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 44.0); meanwhile ABCL is in a Breakdown options structure phase (RSI 33.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABCL leads the Growth & Scale pillar: GAINL posts +68.4% YoY revenue growth and N/A YoY earnings growth on $64M TTM revenue (88.6% gross margin, 42.5% operating margin), compared with ABCL at +18.8% YoY revenue growth and +45.9% YoY earnings growth on $68M TTM revenue (N/A gross margin, -298.0% operating margin). On trailing 12-month operating scale, GAINL generates $64M in USD-normalized revenue versus $68M for ABCL. In operating R&D and SG&A reinvestment, GAINL deploys 46.1% of Rev ($29M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABCL.

ABCL screens cheaper on headline valuation multiples. GAINL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 5.6x EV/Revenue (unreported cash flow margin), whereas ABCL trades at 27.6x Forward P/E, 27.6x Trailing P/E, N/M PEG, and 50.0x EV/Revenue (-48.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GAINL (22.9% ROE) versus ABCL (-14.6% ROE) capital efficiency.

In options market volatility and institutional positioning, GAINL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.02β · 2% Vol realized risk). By comparison, ABCL carries 86.5% implied volatility (32nd %ile, Balanced (25th–60th %ile)), a 0.35x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.32β · 85% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.